Treatment of heavy menstrual bleeding with Unani tablet

Evaluation of efficacy and safety of Qurse bandish e khoon in the management of heavy menstrual Bleeding HMB A double blind randomized standard controlled trial - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055758

Enrollment

Registered

2023-07-27

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N921- Excessive and frequent menstruation with irregular cycle

Interventions

Intervention1: Qurse bandish-e-khoon: 520mg BD for 5 days for 2 consecutive cycles Control Intervention1: Tranexamic acid: 500mg BD for 2 consecutive cycles

Eligibility

Inclusion criteria

Inclusion criteria: Married and unmarried patients of reproductive age women 18to 45 years Heavy menstrual bleeding in terms of amount PBAC score above 100 or duration more than 7 days in duration for at least three months

Exclusion criteria

Exclusion criteria: Malignancy Coagulopathies systemic and metabolic illness Pelvic inflammatory disease Thyroid dysfunctions Severe anaemia Hb less than8gm percentage

Design outcomes

Primary

Measure	Time frame
Change in menstrual blood loss by PBAC ScoreTimepoint: 3 months	—

Secondary

Measure	Time frame
Change in heamogram Change in quality of life by SF12Timepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Khalil Ahmed Hundgund

Luqman Unani Medical College Hospital and Research Center

nikhatinamdar72@gmail.com7795447144

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026